Skip to main content
All lobbying filings

BRISTOL-MYERS SQUIBB COMPANY

Lobbying for BRISTOL-MYERS SQUIBB COMPANY

 Filing 3rd Quarter - Report
3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $3,180,000.00 expenses · posted Oct 20, 2025

Official filing document

 Bills named in this filing 10
  • HR 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
  • HR 4299
    Protecting Patient Access to Cancer and Complex Therapies Act
  • HR 1968
    Full-Year Continuing Appropriations and Extensions Act, 2025
  • S 864
    HELP Copays Act
  • S 526
    Pharmacy Benefit Manager Transparency Act of 2025
  • HR 3521
    Clinical Trial Modernization Act
  • HR 7635
    The 340B PATIENTS Act of 2024
  • HR 3285
    Fairness for Patient Medications Act
  • S 1339
    Pharmacy Benefit Manager Reform Act
 Lobbying activity 6
Health Issues

H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act Discussions regarding H.R.1, One Big Beautiful Bill Act regarding bio-pharmaceutical provisions Biosimilars reimbursement issues H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.1968, lobbied for passage of the Continuing Resolution to include PBM reform

Medicare/Medicaid

Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act Issues related to the six protected classes of medicines under Medicare Part D, regarding all bio-pharmaceutical issues

Taxation/Internal Revenue Code

Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation

Copyright/Patent/Trademark

Intellectual Property Reform concerning bio-pharmaceutical industry

Pharmacy

S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968

Trade (domestic/foreign)

International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem